Johnson & Johnson (JNJ) Shares Bought by Bouchey Financial Group Ltd
Bouchey Financial Group Ltd increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,288 shares of the company’s stock after acquiring an additional 121 shares during the period. Bouchey Financial Group Ltd’s holdings in Johnson & Johnson were worth $435,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Lbmc Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after purchasing an additional 14 shares in the last quarter. Berson & Corrado Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock worth $353,000 after purchasing an additional 19 shares in the last quarter. RB Capital Management LLC boosted its stake in Johnson & Johnson by 0.4% in the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock worth $692,000 after purchasing an additional 24 shares in the last quarter. Finally, Keel Point LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the first quarter. Keel Point LLC now owns 6,402 shares of the company’s stock worth $797,000 after purchasing an additional 24 shares during the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.
Several analysts have recently commented on the company. UBS AG restated a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research note on Saturday. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Citigroup Inc. began coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. Finally, Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a report on Monday, September 18th. Six investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $135.52.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 0.85% during trading on Monday, hitting $131.12. The stock had a trading volume of 2,103,090 shares. The company has a 50-day moving average of $132.79 and a 200 day moving average of $129.43. The company has a market cap of $351.93 billion, a price-to-earnings ratio of 22.19 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the prior year, the company posted $1.74 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a $0.84 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.58%. Johnson & Johnson’s payout ratio is 56.76%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.